LONDON (Reuters) - Britain's healthcare cost watchdog has given its backing to eye drug Lucentis to treat diabetes-related problems after Swiss drugmaker Novartis offered it at a discount to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results